- Home
- ERH vs KZIA Comparison
ERH vs KZIA Comparison
Compare ERH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERH | KZIA |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 93.2M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | ERH | KZIA |
|---|---|---|
| Price | $12.42 | $7.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 20.3K | ★ 106.6K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.64 |
| 52 Week High | $13.07 | $17.40 |
Technical Indicators
Market Signals| Indicator | ERH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 48.70 |
| Support Level | $11.59 | $6.44 |
| Resistance Level | $12.53 | $8.05 |
| Average True Range (ATR) | 0.19 | 0.69 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 88.10 | 30.77 |
Price Performance
Historical ComparisonAbout ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.